Investigational drug · Phase 2
MZE829
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Proteinuric Kidney Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "MZE829"
First trial start
2025
Feb 5, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MZE829", any sponsor or status.
Conditions studied
As listed on its trial records.
- Proteinuric Kidney Disease
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "MZE829" as an intervention, largest first.
Maze TherapeuticsIndustry
NCT06830629 · 74 participants (planned) · Start Feb 5, 2025 · Primary completion Sep 2026
Drug: MZE829 · For: Proteinuric Kidney Disease
Sites: Decatur, Alabama; Huntsville, Alabama; Montgomery, Alabama · 79 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- APOL1 kidney disease: a critical narrative review of molecular mechanisms, clinical heterogeneity, and the emerging therapeutic landscape.
Dogra N, Baranwal M, Ahmad S, et al. · Int Urol Nephrol 2026
Also in development for Proteinuric Kidney Disease
- VX-147Inaxaplin, IXPPhase 32 trials
Vertex Pharmaceuticals · Proteinuric Kidney Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.